BRCA1 and neoplasm: Leveraging the BRCA1-mutated MOLT4 cell line, our data confirmed that the compound 180055 is capable of significantly inhibiting tumor cell proliferation in both in vitro and in vivo models, corroborating the synthetic lethality principle.